share_log

Bristol-Myers Squibb | 8-K: Bristol-Myers Squibb Appoints Phil Holzer as Senior Vice President and Chief Financial Officer of the Company

SEC announcement ·  Feb 15 17:03
Summary by Moomoo AI
Bristol-Myers Squibb Company, a leading pharmaceutical company, announced a significant change in its executive team. Effective February 15, 2024, Mr. Phil Holzer has been appointed as the new Senior Vice President and Controller. Mr. Holzer, who has been with the company since 2001, has held various senior roles, most recently serving as Senior Vice President, Finance, Treasury, and Tax Operations from 2021 to 2024. His extensive experience within the company includes positions such as Chief Audit Officer and Vice President, U.S. Commercialization Finance. The outgoing Senior Vice President and Controller, Ms. Sharon Greenlees, will transition to another role within the company on the same date. The announcement confirms that Mr. Holzer has no familial ties with any director or executive officer of the company and is not involved in any transaction that would require disclosure under SEC regulations.
Bristol-Myers Squibb Company, a leading pharmaceutical company, announced a significant change in its executive team. Effective February 15, 2024, Mr. Phil Holzer has been appointed as the new Senior Vice President and Controller. Mr. Holzer, who has been with the company since 2001, has held various senior roles, most recently serving as Senior Vice President, Finance, Treasury, and Tax Operations from 2021 to 2024. His extensive experience within the company includes positions such as Chief Audit Officer and Vice President, U.S. Commercialization Finance. The outgoing Senior Vice President and Controller, Ms. Sharon Greenlees, will transition to another role within the company on the same date. The announcement confirms that Mr. Holzer has no familial ties with any director or executive officer of the company and is not involved in any transaction that would require disclosure under SEC regulations.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more